# US 2021/0171660 A1 · Targeted delivery methods and compositions for antihistamines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171660 A1
- Document ID: US20210171660A1
- Status: Published application
- Kind: A1
- Application number: 17/175,871
- Filed: 2021-02-15
- Published: 2021-06-10
- Earliest claimed: 2017-12-22
- Assignees: Lipidair, LLC
- Applicants: Lipidair, LLC
- Inventors: Michael Dale Kahil; Tawanda Gumbo
- Web page: https://patentgrep.com/patent/US20210171660A1

## CPC

- C07K 16/4291: {against IgE}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Products, compositions, and methods for using one or more small particles to facilitate the delivery of one or more antihistamines to a human body are disclosed. In some aspects, methods are disclosed that utilize small particles that may be integrated with one or more guiding antibodies that detect and bind to high affinity immunoglobulin E receptors associated with various types of target cells, such as mast cells, basophils, and dendritic cells. Methods in accordance with the present disclosure may use small particles that are configured to contain relatively high concentrations of at least one form of at least one antihistamine and deliver the antihistamine(s) to areas within a human body where one or more actions associated with an allergic reaction may be in progress and/or where one or more actions associated with an allergic reaction may be likely to occur.

## Claims

### Claim 1

A composition comprising
a nanoparticle having an FcεR targeting moiety extending from an external surface of the nanoparticle, and
an antihistamine contained in the nanoparticle.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the antihistamine is selected from the group consisting of azelastine, carbinoxamine, cyproheptadine, desloratadine, emedastine, hydroxyzine, levocabastine, levocabastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, diphenhydramine, fexofenadine, loratadine, and combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the nanoparticle is a liposome.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the targeting moiety is selected from a peptide, a small molecule, and an antibody.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the targeting moiety is a monoclonal antibody that has a dissociation constant selected from 8.15×10−8, 4.21×10−8, 4.75×10−8, 1.88×10−7, and 8.53×10−8 molar as measured by an Octet® RED96 instrument.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the FcεR targeting moiety is an FcεRI targeting moiety.

### Claim 7 (depends on 1)

A formulation comprising the composition of claim 1 formulated for low-dose delivery of antihistamine.

### Claim 8 (depends on 7)

The formulation of claim 7, wherein the antihistamine is selected from the group consisting of azelastine, carbinoxamine, cyproheptadine, desloratadine, emedastine, hydroxyzine, levocabastine, levocabastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, diphenhydramine, fexofenadine, loratadine, and combinations thereof.

### Claim 9 (depends on 7)

The formulation of claim 7, wherein the nanoparticle is a liposome.

### Claim 10 (depends on 9)

The formulation of claim 9, wherein at least one type of antihistamine is in an aqueous core of the liposome and at least a second type of antihistamine is in a lipid bilayer of the liposome.

### Claim 11 (depends on 1, 7)

The formulation of claim 7 further comprising a second composition of claim 1, wherein the nanoparticle of the second composition is configured for an extended release.

### Claim 12 (depends on 7)

The formulation of claim 7 formulated for aerosol delivery.

### Claim 13

A method for treating allergic reactions comprising
obtaining a composition comprising a nanoparticle having an FcεR targeting moiety extending from an external surface of the nanoparticle, and an antihistamine contained in the nanoparticle; and
delivering the composition to an FcεR in a patient.

### Claim 14 (depends on 13)

The method of claim 13 further comprising delivering the antihistamine to a histamine receptor in the patient.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition comprises a second type of antihistamine in the nanoparticle.

### Claim 16 (depends on 13)

The method of claim 13, wherein the targeting moiety is selected from a peptide, a small molecule, and an antibody.

### Claim 17 (depends on 16)

The method of claim 16, wherein the targeting moiety is a monoclonal antibody, the method further comprising binding of the monoclonal antibody to the FcεR to prevent or minimize cross-linking of IgE and release of mediators.

### Claim 18 (depends on 13)

The method of claim 13, wherein the antihistamine is selected from the group consisting of azelastine, carbinoxamine, cyproheptadine, desloratadine, emedastine, hydroxyzine, levocabastine, levocabastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, diphenhydramine, fexofenadine, loratadine, and combinations thereof.

### Claim 19 (depends on 13)

The method of claim 13, wherein the nanoparticle is a liposome.

### Claim 20 (depends on 13)

The method of claim 13, wherein the FcεR is on a target cell selected from the group consisting of a mast cell, a basophil, and a dendritic cell.

### Claim 21 (depends on 13)

The method of claim 13 formulated for low-dose delivery of antihistamine.

### Claim 22 (depends on 21)

The method of claim 21 further comprising administering the formulation to a patient.

### Claim 23 (depends on 22)

The method of claim 22 further comprising delivering the antihistamine to a histamine receptor in the patient.

### Claim 24 (depends on 22)

The method of claim 22 further comprising administering the formulation to the patient a second time after at least two days.

### Claim 25 (depends on 22)

The method of claim 22, wherein the at least one antihistamine is selected from the group consisting of azelastine, carbinoxamine, cyproheptadine, desloratadine, emedastine, hydroxyzine, levocabastine, levocabastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, diphenhydramine, fexofenadine, loratadine, and combinations thereof.

### Claim 26 (depends on 22)

The method of claim 22, wherein the nanoparticle is a liposome.

### Claim 27 (depends on 22)

The method of claim 22 further comprising binding of the antibody to an FcεRI on a target cell to prevent or minimize cross-linking of IgE and release of mediators.

### Claim 28 (depends on 27)

The method of claim 27, wherein the target cell is selected from the group consisting of a mast cell, a basophil, and a dendritic cell.

### Claim 29 (depends on 22)

The method of claim 22 further comprising delivery of the formulation to portions of a respiratory system of the patient.

### Claim 30 (depends on 22)

The method of claim 22 further comprising delivery of the formulation to portions of a systemic circulation of the patient.
